This approval opens a broader scope of applications into functional foods for this scientifically supported ingredient targeting fat mass loss by modulation of the hormones of appetite
Fytexia has announced the Food and Drug Administration (FDA) completed positively the evaluation of GRN001033 for the ingredient DNF-10, a yeast hydrolysate obtained by enzymatic hydrolysis of Saccharomyces cerevisiae.
This approval opens a broader scope of applications into functional foods for this scientifically supported ingredient targeting fat mass loss by modulation of the hormones of appetite.
The GRAS notification confirms the safety of the use of DNF-10 as an ingredient in popcorn, chips, and crackers, meal replacement, snack bars, and dry protein powders for non-alcoholic beverages.
DNF-10 addresses weight management through the regulation of the mediators of satiety. The low molecular weight peptides (<10kDa) from DNF-10® downregulate ghrelin, the inner hunger promoter, and lower the hypothalamic expression of the neuropeptide Y. Over the long term, DNF-10®is proven to maintain the secretion of leptin, a satiety hormone secreted by the fat cells.
Clinical studies demonstrate that a daily intake of 500 mg of DNF-10 significantly decreases the caloric intake of supplemented subjects by 200kcal/day after the first weeks, to reach a total reduction in caloric intake of 600 kcal/day after 2 months (DOI: 10.3746/pnf.2017.22.1.45). This lower intake of food results in significant body weight loss after 4 weeks. Measured with computed tomography, the weight loss is from a reduction in fat mass, rebalancing body composition of the subjects (DOI: 10.1016/j.nut.2013.02.009).
Clinical studies on a total of 135 subjects, published in peer-review journals, are available to support these results. Water-soluble and heat-resistant, DNF-10 is recommended at a dosage of 500 mg/day for the formulation of dietary supplements and now, for a large scope of functional foods.